1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):359.
2. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519-530.
3. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World health organization classification of tumours. pathology and genetics of tumours of the urinary system and male genital organs. IARC Press: ; 2004.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
5. Fergany A, Hafez K, Novick A. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. The Journal of Urology. 2000;163(2):442-445.
6. Stewart SB, Thompson RH, Psutka SP, et al. Evaluation of the national comprehensive cancer network and american urological association renal cell carcinoma surveillance guidelines. JCO.
2014;32(36):4059-4065.
7. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2019;30(5):706-720.
8. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913-924.
9. Suomen syöpärekisterikeskus . https://syoparekisteri.fi/.
35 10. Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the european prospective investigation into cancer and nutrition. Am J Epidemiol. 2008;167(4):438-446.
11. Bergström A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer--a quantitative review. Br J Cancer. 2001;85(7):984-990.
12. Theis RP, Dolwick Grieb SM, Burr D, Siddiqui T, Asal NR. Smoking, environmental tobacco smoke, and risk of renal cell cancer: A population-based case-control study. BMC Cancer.
2008;8:387.
13. Benichou J, Chow WH, McLaughlin JK, Mandel JS, Fraumeni JF. Population attributable risk of renal cell cancer in minnesota. Am J Epidemiol. 1998;148(5):424-430.
14. Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: Analysis of data from the united states, europe, and australia and new zealand. J Am Soc Nephrol. 2003;14(1):197-207.
15. Capitanio U, Montorsi F. Renal cancer. The Lancet. 2016;387(10021):894-906.
16. Leveridge M, Bostrom P, Koulouris G, Finelli A, Lawrentschuk N. Imaging renal cell carcinoma with ultrasonography, CT and MRI. . 2010;7(6):11-21.
17. Schmidbauer J, Remzi M, Memarsadeghi M, et al. Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. Eur Urol. 2008;53(5):1003-1011.
18. Kovacs G, Akhtar M, Beckwith BJ, et al. The heidelberg classification of renal cell tumours.
The Journal of Pathology. 1997;183(2):131-133.
36 19. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital Organs—Part A: Renal, penile, and testicular
tumours. European Urology. 2016;70(1):93-105.
20. Hung RJ, Moore L, Boffetta P, et al. Family history and the risk of kidney cancer: A multicenter case-control study in central europe. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1287-1290.
21. Gago-Dominguez M, Yuan J, Castelao JE, Ross RK, Yu MC. Family history and risk of renal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2001;10(9):1001-1004.
22. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers.
2017;3:17009.
23. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer.
2015;15(1):55-64.
24. Maher E. Hereditary renal cell carcinoma syndromes: Diagnosis, surveillance and management.
. 2018;36(12):11-21.
25. Menko FH, van Steensel M, Giraud S, et al. Birt-hogg-dubé syndrome: Diagnosis and management. Lancet Oncol. 2009;10(12):1199-1206.
26. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von hippel-lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14(15):4726-4734.
27. Young AC, Craven RA, Cohen D, et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res.
2009;15(24):7582-7592.
37 28. Sato Y, Yoshizato T, Shiraishi Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45(8):860-867.
29. Hakimi A, Ostrovnaya I, Reva B, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: A report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013;19(12):3259-3267.
30. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751-759.
31. Hakimi A, Chen Y, Wren J, Gonen M, Abdel-Wahab O, Heguy A. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
European Urology. 2013;63(5):848-854.
32. Kapur P, Pena-Llopis S, Christie A, Zhrebker L. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation. The Lancet Oncology. 2013;14(2):159-167.
33. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. The Journal of Urology. 2000;163(4):1090-1095.
34. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. The Journal of Urology.
2002;168(6):2395-2400.
35. Sobin LH, Gorpodarowich MK, Wittekind Ch. TNM classification of malignant tumors. UICC international union against cancer. 7th edn. Wiley-Blackwell; 2009:255-257.
38 36. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging
manual, 7th edn. . New York, NY: Springer; 2010.
37. Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: Are further improvements needed? European Urology. 2010;58(4):588-595.
38. Delahunt B, Kittelson JM, McCredide MRE, Reeve AE, Stewart JH, Bilous AM. Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: Assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer.
2002;94(3):658-664.
39. Frank I, Blute ML, Leibovich BC, et al. pT2 CLASSIFICATION FOR RENAL CELL CARCINOMA. CAN ITS ACCURACY BE IMPROVED? The Journal of Urology.
2005;173(2):380-384.
40. Brookman-May S, May M, Zigeuner R, et al. Collecting system invasion and fuhrman grade but not tumor size facilitate prognostic stratification of patients with pT2 renal cell carcinoma. The Journal of Urology. 2011;186(6):2175-2181. Accessed May 15, 2020.
41. Waalkes S, Becker F, Schrader AJ, et al. Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? Eur Urol. 2011;59(2):258-263.
42. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, 8th edn. Hoboken: Wiley-Blackwell; 2017.
43. Amin MB, Edge SB, Greene FL, Byrd DR. AJCC cancer staging manual, 8th edn. . Springer New York; 2016.
39 44. Chen L, Li H, Gu L, et al. Prognostic role of urinary collecting system invasion in renal cell carcinoma: A systematic review and meta-analysis. Sci Rep. 2016;6.
45. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han K. Renal cell carcinoma with retroperitoneal lymph nodes: Role of lymph node dissection. The Journal of Urology. 2003;169(6):2076-2083.
46. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. The American Journal of Surgical Pathology. 1982;6(7):655-663. Accessed Oct 8, 2020.
47. Sun M, Lughezzani G, Jeldres C, et al. A proposal for reclassification of the fuhrman grading system in patients with clear cell renal cell carcinoma. European Urology. 2009;56(5):775-781.
48. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. The American Journal of Surgical Pathology. 2003;27(5):612-624.
49. Patard J, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. Journal of Clinical Oncology: Official Journal of the
American Society of Clinical Oncology. 2005;23(12):2763-2771.
50. Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinmoa: Pathological features associated with cancer specific survival. J Urol.
2001;166(2):453-456.
51. Mostofi FK, Davis CJ. Histological typing of kidney tumours. international classification of tumours. 2nd ed. world health organization. Geneva: ; 1998.
40 52. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol. 2011;35(8):1134-1139.
53. Sika-Paotonu D, Bethwaite PB, McCredie MRE, William Jordan T, Delahunt B. Nucleolar grade but not fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol.
2006;30(9):1091-1096.
54. Delahunt B, Cheville JC, Martignoni G, et al. The international society of urological pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol.
2013;37(10):1490-1504.
55. Delahunt B, Srigley JR, Egevad L, Montironi R. International society of urological pathology grading and other prognostic factors for renal neoplasia. European Urology. 2014;66(5):795-798.
56. Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome. The American Journal of Surgical Pathology. 2004;28(4):435–441.
57. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: A study of 101 cases. The American Journal of Surgical Pathology. 2001;25(3):275-284.
58. Tollefson MK, Thompson RH, Sheinin Y, et al. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer. 2007;110(4):783-790.
59. Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 2002;167(1):65-70.
41 60. Keskin SK, Msaouel P, Hess KR, et al. Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: Comparison between the cytokine and targeted therapy eras. J Urol. 2017;198(3):530-537.
61. Pichler M, Hutterer GC, Chromecki TF, et al. Histologic tumor necrosis is an independent prognostic indicator for clear cell and papillary renal cell carcinoma. Am J Clin Pathol.
2012;137(2):283-289.
62. Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005;104(3):511-520.
63. Delahunt B, McKenney JK, Lohse CM, et al. A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. The American Journal of Surgical Pathology.
2013;37(3):311-322.
64. Renshaw AA, Cheville JC. Quantitative tumour necrosis is an independent predictor of overall survival in clear cell renal cell carcinoma. Pathology. 2015;47(1):34-37.
65. Klatte T, Said JW, de Martino M, et al. Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: Higher prognostic accuracy of extent based rather than presence/absence classification. The Journal of Urology. 2009;181(4):1558-1564.
66. Lam JS, Shvarts O, Said JW, et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005;103(12):2517-2525.
67. Klatte T, Remzi M, Zigeuner RE, et al. Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. The Journal of Urology. 2010;184(1):53-58.
42 68. Pichler M, Hutterer GC, Chromecki TF, Pummer K, Mannweiler S, Zigeuner R. Presence and extent of histological tumour necrosis is an adverse prognostic factor in papillary type 1 but not in papillary type 2 renal cell carcinoma. Histopathology. 2013;62(2):219-228.
69. Cheville JC, Blute ML, Zincke H, Lohse CM, Weaver AL. Stage pT1 conventional (clear cell) renal cell carcinmoa: Pathological features associated with cancer specific survival. The Journal of Urology. 2001;166(2):453-456.
70. Sabo E, Boltenko A, Sova Y, Stein A, Kleinhaus S, Resnick MB. Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin Cancer Res.
2001;7(3):533-537.
71. Kroeger N, Rampersaud EN, Patard J, et al. Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: A multicenter investigation. The Journal of Urology. 2012;187(2):418-423.
72. Bedke J, Heide J, Ribback S, et al. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: A validation study in clinical practice. BJU Int. 2018;121(1):84-92.
73. Huang H, Pan X, Huang Y, et al. Microvascular invasion as a prognostic indicator in renal cell carcinoma: A systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(7):10779-10792.
74. Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183(4):1309-1315.
75. Leibovich B, Lohse C, Crispen P, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. The Journal of Urology. 2010;183(4):1309-1316.
43 76. Delahunt B, Eble JN. Papillary renal cell carcinoma: A clinicopathologic and
immunohistochemical study of 105 tumors. Mod Pathol. 1997;10(6):537-544.
77. Klatte T, Pantuck AJ, Said JW, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15(4):1162-1169.
78. Mejean A, Hopirtean V, Bazin JP, Larousserie F, Benoit H. Prognostic factors for the survival of patients with papillary renal cell carcinoma: Meaning of histological typing and multifocality. . J Urol. 2003;170(3):764-7.
79. Wong ECL, Di Lena R, Breau RH, et al. Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2. Urologic Oncology: Seminars and Original Investigations. 2019;37(10):721-726.
80. Delahunt B, Eble J, McCredie M, Bethwaite P, Stewart J. Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases. Human Pathology.
2001;32(6):590-595.
81. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: Prognostic utility of type 1 and type 2 subclassification. Urology. 2007;69(2):230-235.
82. MacLennan S, Imamura M, Lapitan MC, et al. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol. 2012;61(5):972-993.
83. Zini L, Perrotte P, Capitanio U, et al. Radical versus partial nephrectomy: Effect on overall and noncancer mortality. Cancer. 2009;115(7):1465-1471.
84. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: A retrospective cohort study. Lancet Oncol. 2006;7(9):735-740.
44 85. Capitanio U, Terrone C, Antonelli A, et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. Eur Urol. 2015;67(4):683-689.
86. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417-427.
87. Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive
nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME randomized clinical trial. JAMA Oncol. 2019;5(2):164-170.
88. Hanna N, Sun M, Meyer CP, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: A national cancer data base study. J Clin Oncol. 2016;34(27):3267-3275.
89. Kim SH, Park B, Hwang EC, et al. Retrospective multicenter long-term follow-up analysis of prognostic risk factors for recurrence-free, metastasis-free, cancer-specific, and overall survival after curative nephrectomy in non-metastatic renal cell carcinoma. Front Oncol. 2019;9:859.
90. Kanamaru H, Akino H, Suzuki Y, Noriki S, Okada K. Prognostic value of nuclear area index in combination with the world health organization grading system for patients with renal cell
carcinoma. Urology. 2001;57(2):257-261. Accessed Dec 5, 2020.